For patients whose cancers have stopped responding to chemotherapy or immunotherapy, the search for new vulnerabilities in tumor cells is urgent. A growing body of evidence suggests that iron-dependent cell death — ferroptosis — may expose exactly those weaknesses, and a new comprehensive review maps how specific oncogenic mutations determine whether a tumor embraces or evades this pathway. The implications could reshape how oncologists match therapies to tumor genotypes.

The review synthesizes the molecular architecture of ferroptosis across thirteen cancer types, focusing on how key regulators — notably the enzyme GPX4 (glutathione peroxidase 4), the cystine-glutamate transporter system Xc⁻, and iron-trafficking proteins — maintain the critical equilibrium between oxidative lipid damage and cellular antioxidant defense. What distinguishes this analysis is its mutation-level resolution: oncogenic variants in EGFR, KRAS, TP53, KEAP1, and IDH1 are each shown to rewire ferroptosis susceptibility through distinct mechanisms, including shifts in redox homeostasis, metabolic reprogramming, and tumor microenvironment remodeling. A KRAS-mutant pancreatic tumor, for instance, engages different ferroptosis dynamics than a TP53-null colorectal lesion — a distinction with direct therapeutic consequences.

Placing this review in broader context, ferroptosis research has accelerated sharply since the pathway was formally named in 2012, yet clinical translation remains nascent. The central limitation of this work is its review format — it synthesizes existing preclinical and early clinical data rather than generating new experimental evidence, meaning causal claims require validation in prospective trials. Many cited findings derive from cell-line or mouse models, which notoriously overpredict drug efficacy. Nevertheless, the mutation-specific framework proposed here is clinically actionable in principle, particularly as tumor genotyping becomes routine. If GPX4 inhibitors or system Xc⁻ blockers can be stratified by driver mutation profile, ferroptosis-based regimens could offer a meaningful route around acquired resistance — an incremental but strategically important advance for precision oncology.